Hostname: page-component-586b7cd67f-vdxz6 Total loading time: 0 Render date: 2024-11-22T08:11:00.509Z Has data issue: false hasContentIssue false
  • English
  • Français

An Interim Analysis of the Quality of Life, Effectiveness, Safety, and Tolerability (QU.E.S.T.) Evaluation of Mixed Amphetamine Salts Extended Release in Adults With ADHD

Published online by Cambridge University Press:  07 November 2014

David W. Goodman ,
Lawrence Ginsberg ,
Richard H. Weisler ,
Andrew J. Cutler  and
Paul Hodgkins
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective: Evaluate safety and efficacy of mixed amphetamine salts extended release (MAS XR) in adults with attention-deficit/hyperactivity disorder (ADHD).

Methods: 10-week interim analysis of the Quality of life, Effectiveness, Safety, and Tolerability (QU.E.S.T.) trial, an ongoing, 30-week, open-label, multicenter investigation of once-daily MAS XR (10–60 mg/day) in adults (≥18 years of age) with ADHD in community practice settings.

Findings: With up to 10 weeks of open-label MAS XR 10 to 60 mg/day (final visit mean dose: 37.2 mg/day), 725 adults exhibited rapid, sustained improvement in ADHD symptoms. At end point, significant decreases from baseline were seen in ADHD Rating Scale IV total scores (-19.8±11.6; P<.0001), hyperactivity/impulsivity subscak (-8.1±6.1; P<.0001), and inattentive subscale (-11.6±6.7; P<.0001). Most subjects (74.4%) were rated as very much/much improved. Based on the 36- item Short Form Health Survey (version 2), significant improvements in quality of life were seen in the domains of general health, physical and mental health, vitality, and social, emotional and physical role functioning (P<.0001). Few subjects (6.9%) withdrew due to adverse events; the most common MAS XR-related adverse events were decreased appetite and dry mouth (19.2% each), insomnia (17.8%), and headache (16.8%).

Conclusion: In adults with ADHD, MAS XR treatment is generally safe and demonstrates significant improvement in ADHD symptoms and related quality of life.

Type
Academic Supplement
Information
CNS Spectrums , Volume 10 , Issue S20: Mixed Amphetamine Salts Extended Release for the Treatment of ADHD in Adults: Current Evidence , December 2005 , pp. 26 - 34
Copyright
Copyright © Cambridge University Press 2005

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1. Rowland, AS, Lesesne, CA, Abramowitz, AJ. The epidemiology of attention-deficit/hyperactivity disorder (ADHD): a public health view. Ment Retard Dev Disabil Res Rev. 2002;8(3):162–170.CrossRefGoogle ScholarPubMed
2. Dulcan, M.Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder. American Academy of Child and Adolescent Psychiatry. J Am Acad Child Adolesc Psychiatry. 1997;36(10 suppl):85S–121S.CrossRefGoogle ScholarPubMed
3. Biederman, J, Faraone, S, Milberger, S, et al. Predictors of persistence and remission of ADHD into adolescence: results from a four-year prospective follow-up study. J Am Acad Child Adolesc Psychiatry. 1996;35(3):343–351.CrossRefGoogle ScholarPubMed
4. Kessler, RC.Prevalence of adult ADHD in the United States: results from the National Comorbidity Survey Replication (NCS-R). Presentation at: 157th Annual Meeting of the American Psychiatric Association; May 1-6,2004; New York, NY.Google Scholar
5. Faraone, SV, Biederman, J, Spencer, T, et al. Dose-response efficacy of mixed amphetamine salts XR in adults with ADHD. Poster presented at: 157th Annual Meeting of the American Psychiatric Association; May 1-6, 2004; New York, NY.Google Scholar
6. United States Census Bureau: Census 2000 Summary File 4. Available at: http://fact-finder.census.gov. Accessed August 16, 2004.Google Scholar
7. Biederman, J, Faraone, SV, Monuteaux, MC, Bober, M, Cadogen, E.Gender effects on attention-deficit/hyperactivity disorder in adults, revisited. Biol Psychiatry. 2004;55(7):692–700.CrossRefGoogle Scholar
8. Barkley, RA.Major life activity and health outcomes associated with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2002;63(suppl 12):10–15.Google ScholarPubMed
9. Montano, B.Diagnosis and treatment of ADHD in adults in primary care. J Clin Psychiatry. 2004;65(suppl 3):18–21.Google ScholarPubMed
10. Beck, C, Silverstone, P, Glor, K, et al. Psychostimulant prescriptions by psychiatrists higher than expected: a self-report survey. Can J Psychiatry. 1999;44(7):680–684.CrossRefGoogle ScholarPubMed
11. Spencer, T, Wilens, T, Biederman, J, Faraone, SV, Ablon, JS, Lapey, K.A double-blind, crossover comparison of methyiphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder. Arch Gen Psychiatry. 1995;52(6):434–443.CrossRefGoogle ScholarPubMed
12. Wilens, TE, Biederman, J, Spencer, TJ, et al. Controlled trial of high doses of pemoline for adults with attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 1999;19(3):257–264.CrossRefGoogle ScholarPubMed
13. Spencer, T, Biederman, J, Wilens, T, et al. Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder, Arch Gen Psychiatry. 2001;58(8):775–782.CrossRefGoogle ScholarPubMed
14. Weisler, RH, Biederman, J, Spencer, T, et al. Adderall XR dosed once daily in adult patients with ADHD. Presentation at: the 156th Annual Meeting of the American Psychiatric Association; May 20, 2003; San Francisco, CA.Google Scholar
15. Biederman, J.Mixed amphetamine salts XR in adults with ADHD: 18-month interim analysis. Presented at: 157th Annual Meeting of the American Psychiatric Association; May 1-6, 2004; New York, NY.Google Scholar
16. Biederman, J, Mick, E, Faraone, SV.Age dependent decline of ADHD symptoms revisited: impact of remission definition and symptom type. Am J Psychiatry. 2000;157(5):816–818.CrossRefGoogle Scholar
17. Diagnostic and Statistical Manual far Mental Disorders. 4th ed text rev. Washington, DC: American Psychiatric Association; 2000.Google Scholar
18. DuPaul, GJ, Power, T, Anastopoulos, A, Reed, R.The ADHD Rating Scale-IV Checklist, Norms and Clinical Interpretation. New York, NY; Guilford Press; 1998.Google Scholar
19. Jenkinson, C, Stewart-Brown, S, Petersen, S, Paice, C.Assessment of the SF-36 version 2 in the United Kingdom. J Epidemiol Community Health. 1999;53(1):46–50.CrossRefGoogle ScholarPubMed
20. Jensen, P.Longer term effects of stimulant treatments for Attention-Deficit/Hyperactivity Disorder.) Atten Disord. 2002;6(suppl 1):S45–S56.CrossRefGoogle ScholarPubMed
21. Wilens, T, Pelham, W, Stein, M, et al. ADHD treatment with once-daily OROS methylphenidate: interim 12-month results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry. 2003;42(4):424–433.CrossRefGoogle ScholarPubMed